Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis

Bandeira, Isabelle Pastor; Franzoi, André Eduardo de Almeida; Wollmann, Giulia Murillo; Medeiros, Washigton Luiz Gomes de; Brandão, Wesley Nogueira; Peron, Jean Pierre Schatzmann; Becker, Jéfferson; Nascimento, Osvaldo J. M.; Gonçalves, Marcus Vinícius Magno

doi:10.1007/s10072-022-06276-5

Cited by 4 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible interaction between IL31 and sCD40L in the proinflammatory state in MS is discussed. We also describe the justification for this hypothesis and whether it is possible to investigate these cytokines as biomarkers of MS (Pastor Bandeira et al, 2022). Increased EBV-encoded nuclear antigen-1 (EBNA1)-specific IgG responses can predict conversion from CIS to MS.…”

Section: Soluble Cd40l (Scd40l)mentioning

confidence: 99%

Biomarkers in Multiple Sclerosis: Analysis of the Present Advantages and Look to the Future

2023

J Psychol Neurosci

View full text Add to dashboard Cite

MS is a chronic heterogeneous demyelinating disease of the CNS among the young population, manifested by unpredictable attacks and subsequent remissions (McGinley et al., 2021; Lublin et al., 2022). The disease develops as a result of an interaction between genetic and environmental factors (Dobson et al., 2019). The most important genetic risk factor are the alleles of genes encoding human leucocyte antigens (HLAs), especially HLA-DRB1*1501 (Hollenbach et al., 2015). The main exogenous noxes that have the potential to trigger the illness are Epstein Barr Virus (EBV) infection, tobacco use, obesity since childhood, low vitamin D levels. Inflammatory infiltrates within the brain lesions contain CD4 and CD8 T-lymphocytes, activated monocytes and B-lymphocytes which lead to disruption of the myelin sheaths covering the nerves (Housley et al., 2015). It is considered that EBV infection contributes to production of B cells that provokes the activation of CNS inflammatory processes (Leffler et al., 2022). A relationship between gut microbiome-derived short-chain fatty acids (SCFAs) and immune dysfunction in patients with early MS was proposed (Trend et al., 2021). According to a recent hypothesis the EBV infection and B-cell dysfunction connect with gut-associated lymphoid tissue leading to aberrant B-cell responses that guide pathogenic T-cell responses in the CNS (Leffler et al., 2022).

show abstract

Section: Soluble Cd40l (Scd40l)mentioning

confidence: 99%

Biomarkers in Multiple Sclerosis: Analysis of the Present Advantages and Look to the Future

2023

J Psychol Neurosci

View full text Add to dashboard Cite

show abstract

Interleukin (IL)-23, IL-31, and IL-33 Play a Role in the Course of Autoimmune Endocrine Diseases

Janyga,

Kajdaniuk,

Czuba

et al. 2024

EMIDDT

View full text Add to dashboard Cite

Background: Interleukins (IL)-23, 31, and 33 are involved in the regulation of T helper 17 (Th17)/regulatory T (Treg) cells balance. The role of IL-23, 31 and 33 in non-endocrine autoimmune diseases has been confirmed. Data on the involvement of these cytokines in endocrine autoimmune diseases are limited. Objective: This study aimed to determine the involvement of cytokines regulating the T helper 17 (Th17)/regulatory T (Treg) cells axis in the course of autoimmune endocrine diseases. Methods: A total number of 80 participants were divided into 4 groups: the autoimmune polyendocrine syndrome (APS) group consisting of APS type 2 (APS-2) and type 3 (APS-3) subgroups, the Hashimoto's thyroiditis (HT) group, the Graves’ disease (GD) group and the control (C) group. Fifteen cytokines related to Th17 and Treg lymphocytes were determined in the serum of all participants. Results: Higher levels of IL-23 and IL-31 were found in the APS, GD, and HT groups compared to the C group. Higher levels of IL-23 and IL-31 were also observed in the APS-2 group, in contrast to the APS-3 group. Correlation analysis of variables in the groups showed a statistically significant correlation between the cytokines IL-23, IL-31, and IL-33 in the APS and APS-2 groups, but no correlation in the APS-3 and C groups. Conclusion: IL-23 and IL-31 are independent factors in the course of HT, GD, and APS-2, in contrast to APS-3. The positive correlation between IL-23 and IL-31, IL-23 and IL-33, and between IL-31 and IL-33 in the APS, APS-2 groups, but the lack of correlation in the APS-3 and C groups may further suggest the involvement of these cytokines in the course of Addison's disease.

show abstract

Soluble CD40 Ligand as a Promising Biomarker in Cancer Diagnosis

Pazoki,

Dadfar,

Shadab

et al. 2024

Cells

View full text Add to dashboard Cite

Cancer remains a significant challenge in medicine due to its complexity and heterogeneity. Biomarkers have emerged as vital tools for cancer research and clinical practice, facilitating early detection, prognosis assessment, and treatment monitoring. Among these, CD40 ligand (CD40L) has gained attention for its role in immune response modulation. Soluble CD40 ligand (sCD40L) has shown promise as a potential biomarker in cancer diagnosis and progression, reflecting interactions between immune cells and the tumor microenvironment. This review explores the intricate relationship between sCD40L and cancer, highlighting its diagnostic and prognostic potential. It discusses biomarker discovery, emphasizing the need for reliable markers in oncology, and elucidates the roles of CD40L in inflammatory responses and interactions with tumor cells. Additionally, it examines sCD40L as a biomarker, detailing its significance across various cancer types and clinical applications. Moreover, the review focuses on therapeutic interventions targeting CD40L in malignancies, providing insights into cellular and gene therapy approaches and recombinant protein-based strategies. The clinical effectiveness of CD40L-targeted therapy is evaluated, underscoring the need for further research to unlock the full potential of this signaling pathway in cancer management.

show abstract

Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis

Cited by 4 publications

References 72 publications

Biomarkers in Multiple Sclerosis: Analysis of the Present Advantages and Look to the Future

Biomarkers in Multiple Sclerosis: Analysis of the Present Advantages and Look to the Future

Interleukin (IL)-23, IL-31, and IL-33 Play a Role in the Course of Autoimmune Endocrine Diseases

Soluble CD40 Ligand as a Promising Biomarker in Cancer Diagnosis

Contact Info

Product

Resources

About